FDA issues CRL on Atara (NASDAQ: ATRA) EBVALLO tabelecleucel BLA

Rhea-AI Filing Summary

Atara Biotherapeutics, Inc. filed a current report describing two developments. The company provided a preliminary estimate of its cash, cash equivalents and short-term investments as of December 31, 2025, explaining that this early figure does not include all information needed to fully understand its year-end financial condition or fourth-quarter results.

Atara also reported that the U.S. Food and Drug Administration issued a Complete Response Letter for the Biologics License Application for EBVALLO™ (tabelecleucel). This means the application was not approved in its current form and further action would be required before EBVALLO could be considered again for U.S. approval. The company disclosed this regulatory and business update via a press release attached as an exhibit.

Positive

• None.

Negative

• FDA Complete Response Letter for EBVALLO BLA — The U.S. Food and Drug Administration issued a Complete Response Letter for Atara’s EBVALLO™ (tabelecleucel) Biologics License Application, meaning it was not approved in its current form.

Insights

Biotech regulatory analyst

FDA issues a Complete Response Letter on Atara's EBVALLO BLA, delaying any potential U.S. approval while year-end cash data is only preliminary.

The report explains that Atara Biotherapeutics received a Complete Response Letter from the U.S. Food and Drug Administration for its Biologics License Application for EBVALLO™ (tabelecleucel). A Complete Response Letter indicates the agency has completed its review but will not approve the application in its present form, so the product cannot be marketed in the United States based on this submission.

This outcome is typically a significant setback for a late-stage therapy because it halts the approval process until the sponsor addresses the FDA’s concerns, which may require additional data, analyses, or changes to the application as described in the letter. The filing does not detail those specific requirements, but simply notes the existence of the Complete Response Letter and references a press release with further information.

The company also announced a preliminary estimate of its cash, cash equivalents and short-term investments as of December 31, 2025, while emphasizing that this early figure does not provide a complete view of its financial condition or results for the quarter then ended. Subsequent financial statements and disclosures for the period ended December 31, 2025, will be important to understand how the company is positioned to navigate the additional regulatory steps implied by the Complete Response Letter.

false 0001604464 0001604464 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-36548		46-0920988
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1280 Rancho Conejo Blvd
Thousand Oaks, California		91320
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ATRA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

In connection with the press release described in Item 8.01 below, on January 12, 2026, Atara Biotherapeutics, Inc. (the “Company”) announced its cash, cash equivalents and short term investments as of December 31, 2025. The preliminary estimate is based on currently available information and does not present all necessary information for a complete understanding of the Company’s financial condition as of December 31, 2025 or the Company’s results of operations for the fourth quarter ended December 31, 2025.

Item 8.01 Other Events

On January 12, 2026, the Company issued a press release titled “Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO^™ (tabelecleucel)” announcing that the U.S. Food and Drug Administration issued a Complete Response Letter for the EBVALLO^™ (tabelecleucel) Biologics License Application. A copy of the press release is filed as Exhibit 99.1 and incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ATARA BIOTHERAPEUTICS, INC.
Date: January 12, 2026				By:		/s/ AnhCo Thieu Nguyen
						AnhCo Thieu Nguyen President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)

FAQ

What did Atara Biotherapeutics (ATRA) announce about EBVALLO in this 8-K?

Atara Biotherapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter for its EBVALLO™ (tabelecleucel) Biologics License Application, indicating the application was not approved in its current form.

What is a Complete Response Letter in the context of Atara’s EBVALLO application?

A Complete Response Letter is the U.S. Food and Drug Administration’s formal notification that it has completed its review of a marketing application but will not approve it in its present form. In this case, it applies to Atara’s EBVALLO™ (tabelecleucel) Biologics License Application.

Did Atara Biotherapeutics provide any financial information in this 8-K filing?

Yes. Atara Biotherapeutics announced a preliminary estimate of its cash, cash equivalents and short-term investments as of December 31, 2025, while noting that this estimate does not include all information needed to fully understand its financial condition or fourth-quarter results.

How did Atara Biotherapeutics communicate the EBVALLO regulatory update?

The company issued a press release titled “Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel),” which it attached as Exhibit 99.1 and incorporated by reference.

Does this 8-K explain the specific issues raised by the FDA for EBVALLO?

The report states only that the U.S. Food and Drug Administration issued a Complete Response Letter for the EBVALLO Biologics License Application and refers to the attached press release; it does not describe the specific issues in the letter.

What time period does Atara’s preliminary cash disclosure relate to?

The preliminary estimate of cash, cash equivalents and short-term investments relates to Atara’s financial position as of December 31, 2025, and is connected to its results for the fourth quarter then ended.